A cathepsin K inhibitor reduces breast cancer-induced osteolysis and skeletal tumor burden

Cancer Research

Volumn 67, Issue 20, 2007, Pages 9894-9902

  Le Gall, Céline ^a,b   Bellahcène, Akeila ^c   Bonnelye, Edith ^a,b   Gasser, Jürg A ^d   Castronovo, Vincent ^c   Green, Jonathan ^d   Zimmermann, Johann ^d   Clézardin, Philippe ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ LYON 1   (France)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN K INHIBITOR; DRUG VEHICLE; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; BONE TUMOR; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CATHEPSINS; CELL LINE, TUMOR; CYSTEINE PROTEINASE INHIBITORS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; OSTEOLYSIS; RANDOM ALLOCATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 35448959223     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3940     Document Type: Article

References (29)

1. Brown JE, Neville-Webbe H, Coleman RE. The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer 2004;11:207-24.
2. Mundy GR. Metastasis to bone: causes, consequences, and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93.
3. Bendre SM, Gaddy-Kurten D, Mon-Foote T, et al. Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res 2002;62:5571-9.
4. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-49.
5. Hiraga T, Myyoui A, Choi ME, Yoshikawa H, Yoneda T. Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-β enhances bone metastases in breast cancer. Cancer Res 2006;66:2067-73.
6. Boucharaba A, Serre CM, Grès S, et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 2004;114:1714-25.
7. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289:1504-8.
8. Saftig P, Hunziker E, Wehmeyer O, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A 1998;95:13453-8.
9. Kavanagh KL, Guo K, Dunford JE, et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A 2006;103:7829-34.
10. Rondeau JM, Bitsch F, Bourgier E, et al. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. Chem Med Chem 2006;1:267-73.
11. Grabowska UB, Chambers TJ, Shiroo M. Recent developments in cathepsin K inhibitor design. Curr Opin Drug Discovery Dev 2005;8:619-30.
12. Littlewood-Evans AJ, Bilbe G, Bowler WB, et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res 1997;57:5386-90.
13. Grosios K, Altmann E, Gasser JA, Stumm M, Zimmermann J. Efficacy of the bisphosphonate Zometa and the selective cathepsin K inhibitor AFG495 administered alone or in combination in a murine xenograft model of breast cancer cell induced osteolysis. Proc Am Assoc Cancer Res 2005;46:Abs2910.
14. Pécheur I, Peyruchaud O, Serre CM, et al. Integrin αvβ3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEBJ 2002;16:1266-8.
15. Peyruchaud O, Serre CM, NicAmhlaoibh R, Fournier P, Clézardin P. Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity. J Biol Chem 2003;278:45826-32.
16. Daubiné F, Le Gall C, Gasser J, Green J, Clézardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007;99:322-30.
17. Brubaker KD, Vessella RL, True LD, Thomas R, Corey E. Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Min Res 2003;18:222-30.
18. Delaissé JM, Andersen TL, Engsig MT, Henriksen K, Troen T, Blavier L. Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclast activities. Microsc Res Techniq 2003;61:504-13.
19. Everts V, Korper W, Hoeben KA, et al. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone. J Bone Min Res 2006;21:1399-1408.
20. Yeung F, Law WK, Yeh CH, et al. Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. J Biol Chem 2002;277:2468-76.
21. Barnes GL, Hebert KE, Kamal M, et al. Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease. Cancer Res 2004;64:4506-13.
22. Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclasto-genesis and prevents prostate tumor growth in the bone. J Clin Invest 2001;107:1235-44.
23. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001;61:4432-6.
24. Yonou H, Kanomata N, Goya M, et al. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Res 2003;63:2096-102.
25. Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006;440:692-6.
26. Bauss F, Wagner M, Hothorn LH. Total administered dose of ibandronate determines its effect on bone mass and architecture in ovariectomized aged rats. J Rheumatol 2002;29:990-8.
27. Adami S, Supronik J, Hala T, et al. Effect of one year treatment with the cathesin-K inhibitor, balicatib, on bone mineral density in postmenopausal women with osteopenia/osteoporosis. J Bone Min Res 2006;21:Abs1085.
28. Clézardin P, Ebetino FH, Fournier PGJ. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 2005;65:4971-4.
29. Kim SJ, Uehara H, Yazici S, et al. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. Cancer Res 2005;65:3707-15.